<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813967</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCH-E-E</org_study_id>
    <nct_id>NCT02813967</nct_id>
  </id_info>
  <brief_title>S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer</brief_title>
  <official_title>S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Prospective, Randomized, Multi-center Phase-III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomised, multicenter, phase 3 trial. Patients who were age of 70 years or older
      with histologically confirmed esophageal cancer were randomly assigned to S-1 concurrent with
      radiotherapy or radiotherapy alone.The primary endpoint was overall survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>assessed with the European Organisation for Research and Treatment of Cancer quality-of-life core questionnaire QLQ-C30</description>
  </other_outcome>
  <other_outcome>
    <measure>the oesophagus-specific quality-of-life</measure>
    <time_frame>5 years</time_frame>
    <description>assessed with the European Organisation for Research and Treatment of Cancer quality-of-life the oesophagus-specific questionnaire QLQ-OES18</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Chemoradiation</condition>
  <arm_group>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy 60 Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy 54 Gy</intervention_name>
    <description>Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.</description>
    <arm_group_label>chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy 60 Gy</intervention_name>
    <description>Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.</description>
    <arm_group_label>Radiotherapy 60 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 70mg/m2 was administered on days 1-14 and 29-42.</description>
    <arm_group_label>chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytologic diagnosis of esophageal carcinoma

          -  ECOG performance status 0-1

          -  Age:70-85 years

          -  Joined the study voluntarily and signed informed consent form

          -  Patients must not have received any prior anticancer therapy

          -  Stage Ⅰ-ⅣB（AJCC 2009）

          -  Target lesions can be measured according to RECIST criteria

          -  No serious system dysfunction and immuno-deficiency, Adequate organ function including
             the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet
             count ≥100x 109/L, TBIL&lt;1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN

        Exclusion Criteria:

          -  Multiple carcinomas of the esophagus,

          -  Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula,

          -  Metastatic disease (M1b),

          -  A primary tumor that extended to within 2 cm of the gastroesophageal junction,

          -  Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor,

          -  history of a second malignancy other than nonmelanoma skin cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MING CHEN, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>XIANGHUI DU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>youngling JI, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>weiguo zhu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Huaian first people's hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MING CHEN, PHD</last_name>
    <phone>0086-571-88122068</phone>
    <email>chenming@zjcc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>XIANGHUI DU, MD</last_name>
    <phone>0086-571-88128181</phone>
    <email>duxianghui88@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chen, M.D.</last_name>
      <phone>0086-571-88122068</phone>
      <email>gzcm@263.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

